AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39316284 — intervention group
Group type: COMPARATOR
Intervention: tramadol 100 mg QID
Number of subjects: 551
Study 39316284 — intervention group
Group type: COMPARATOR
Intervention: celecoxib 100 mg BID
Number of subjects: 551
Study 39316284 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 551
Study 39316289 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Number of subjects: 333
Study 39316288 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss interventions from SCALE and STEP 1 studies
Number of subjects: 0
Study 39316293 — intervention group
Group type: EXPERIMENTAL
Intervention: Macitentan and Tadalafil (M+T)
Number of subjects: 1336
Study 39316400 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice-activated, internet-delivered cognitive behavioral therapy for insomnia (CBT-I) program for 6 weeks
Number of subjects: 76
Study 39316400 — intervention group
Group type: COMPARATOR
Intervention: Educational control for 6 weeks
Number of subjects: 76
Study 39316536 — intervention group
Group type: EXPERIMENTAL
Intervention: Flower printing activities, 60 min once a week for 1 month
Number of subjects: 42
Study 39316536 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 42
Study 39316653 — intervention group
Group type: EXPERIMENTAL
Intervention: SJ low-risk therapy for NCI high-risk patients with ETV6::RUNX1
Number of subjects: 518
Study 39316653 — intervention group
Group type: EXPERIMENTAL
Intervention: SJ standard/high-risk therapy for NCI high-risk patients with high-hyperdiploid B-ALL
Number of subjects: 518
Study 39316653 — intervention group
Group type: COMPARATOR
Intervention: SJ standard-risk therapy for NCI standard-risk patients with high-hyperdiploid B-ALL
Number of subjects: 518
Study 39316653 — intervention group
Group type: EXPERIMENTAL
Intervention: SJ low-risk therapy for NCI high-risk patients with high-hyperdiploid B-ALL
Number of subjects: 518
Study 39316653 — intervention group
Group type: EXPERIMENTAL
Intervention: SJ low-risk therapy
Number of subjects: 518
Study 39316653 — intervention group
Group type: EXPERIMENTAL
Intervention: Contemporary MRD-directed therapy
Number of subjects: 518
Study 39316653 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity regimen for NCI high-risk patients
Number of subjects: 518
Study 39316666 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Number of subjects: 652
Study 39316666 — intervention group
Group type: COMPARATOR
Intervention: Ibrutinib
Number of subjects: 652
Study 39316768 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine and venetoclax (low-dose regimen)
Number of subjects: 0
Study 39316773 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivacaftor 150mg BID for 12 weeks
Number of subjects: 40
Study 39316773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 39316773 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Number of subjects: 40
Study 39316783 — intervention group
Group type: EXPERIMENTAL
Intervention: MIMIC intervention
Number of subjects: 400
Study 39316889 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity electrical stimulation (LIES) group
Number of subjects: 38
Study 39316889 — intervention group
Group type: COMPARATOR
Intervention: Traditional en-masse retraction (TRAD) group
Number of subjects: 38
Study 39316931 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmatched cohort (females)
Number of subjects: 9697
Study 39316931 — intervention group
Group type: COMPARATOR
Intervention: Unmatched cohort (males)
Number of subjects: 9697
Study 39316931 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched cohort (females)
Number of subjects: 9697
Study 39316931 — intervention group
Group type: COMPARATOR
Intervention: Matched cohort (males)
Number of subjects: 9697
Study 39316931 — intervention group
Group type: EXPERIMENTAL
Intervention: Both cohorts (females and males)
Number of subjects: 9697
Study 39316947 — intervention group
Group type: EXPERIMENTAL
Intervention: Deviant long tones
Number of subjects: 484
Study 39316947 — intervention group
Group type: COMPARATOR
Intervention: Standard pitch tones
Number of subjects: 484
Study 39317226 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive vestibular rehabilitation
Number of subjects: 30
Study 39317226 — intervention group
Group type: COMPARATOR
Intervention: Standard vestibular rehabilitation
Number of subjects: 30
Study 39317226 — intervention group
Group type: COMPARATOR
Intervention: No exercise (Control group)
Number of subjects: 30
Study 39317439 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous-intensity cycling exercise for 8 weeks
Number of subjects: 14
Study 39317492 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC)
Number of subjects: 234
Study 39317492 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC with early high-dose intravenous vitamin C (200 mg/kg per day, within 6 hours after return of spontaneous circulation, for 3 days)
Number of subjects: 234
Study 39317492 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC with early high-dose intravenous vitamin C
Number of subjects: 234
Study 39317491 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 1572
Study 39317491 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 1572
Study 39317507 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative stereotactic radiotherapy (12 Gy) to a 4 cm area around the future pancreatic neck transection margin.
Number of subjects: 33
Study 39317508 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus Group Discussions (FGDs)
Number of subjects: 60
Study 39317633 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib 200 mg and abiraterone acetate 1000 mg plus prednisone 10 mg (AAP)
Number of subjects: 0
Study 39317830 — intervention group
Group type: EXPERIMENTAL
Intervention: ClearSight monitor
Number of subjects: 30
Study 39317833 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual-care PR
Number of subjects: 30
Study 39317994 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Interference Therapy (MIT)
Number of subjects: 28
Study 39317994 — intervention group
Group type: COMPARATOR
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 28
Study 39318203 — intervention group
Group type: EXPERIMENTAL
Intervention: EuCorVac-19 (ECV-19) vaccine
Number of subjects: 0
Study 39318203 — intervention group
Group type: COMPARATOR
Intervention: COVISHIELD
Number of subjects: 0
Study 39318387 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib plus atezolizumab
Number of subjects: 112
Study 39318387 — intervention group
Group type: COMPARATOR
Intervention: Single-agent cabozantinib
Number of subjects: 112
Study 39318595 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (discontinued empirical anti-MRSA therapy if nasal swab result is negative)
Number of subjects: 76
Study 39318595 — intervention group
Group type: COMPARATOR
Intervention: Control group (empirical treatment with linezolid or vancomycin)
Number of subjects: 76
Study 39318593 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop oxygen control
Number of subjects: 33
Study 39318593 — intervention group
Group type: COMPARATOR
Intervention: Manual oxygen titrations
Number of subjects: 33
Study 39318718 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-Related Quality-of-Life Utility Values
Number of subjects: 0
Study 39318719 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial inulinase supplementation (2000 inulinase activity units, twice daily for 4 weeks)
Number of subjects: 60
Study 39318719 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice daily for 4 weeks)
Number of subjects: 60
Study 39318719 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial inulinase supplementation
Number of subjects: 60
Study 39318719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 39318787 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment (IPT)
Number of subjects: 746
Study 39318787 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and treating only students with detected infections (IST) with hs-RDT
Number of subjects: 746
Study 39318787 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 746
Study 39318788 — intervention group
Group type: EXPERIMENTAL
Intervention: RMC-035 (1.3 or 0.65 mg/kg)
Number of subjects: 177
Study 39318788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study 39318788 — intervention group
Group type: EXPERIMENTAL
Intervention: RMC-035
Number of subjects: 177
Study 39319046 — intervention group
Group type: EXPERIMENTAL
Intervention: Itepekimab (human monoclonal antibody against IL-33)
Number of subjects: 0
Study 39319046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39319217 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma 24-microRNA signature classifier (MSC)
Number of subjects: 1024
Study 39319217 — intervention group
Group type: EXPERIMENTAL
Intervention: MSC+ participants
Number of subjects: 1024
Study 39319279 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 10 mg/day for patients weighing 10-20 kg (Group 1)
Number of subjects: 0
Study 39319279 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg/day for patients weighing ≥20 kg (Group 2)
Number of subjects: 0
Study 39319279 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 10 mg/day for patients previously diagnosed with GU and/or DU (Group 3)
Number of subjects: 0
Study 39319279 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg/day for patients previously diagnosed with GU and/or DU (Group 4)
Number of subjects: 0
Study 39319356 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription Digital Therapeutic (PDT; Somryst)
Number of subjects: 1565
Study 39319453 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PCI stent edge maxLCBI
Number of subjects: 768
Study 39319453 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-PCI or post-PCI measures of lipid content
Number of subjects: 768
Study 39319453 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid content in untreated nonobstructive coronary artery lesions
Number of subjects: 768
Study 39319453 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual in-stent or stent edge lipid
Number of subjects: 768
Study 39319453 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater stent edge-related lipid and uncovered plaque burden
Number of subjects: 768
Study 39319469 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 375
Study 39319469 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 375
Study 39319493 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization for myocardial infarction
Number of subjects: 314
Study 39319493 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month follow-up after hospitalization
Number of subjects: 314
Study 39319513 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based narrowband UV-B phototherapy
Number of subjects: 783
Study 39319513 — intervention group
Group type: COMPARATOR
Intervention: Office-based narrowband UV-B phototherapy
Number of subjects: 783
Study 39319904 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide (Ca(OH)2)
Number of subjects: 20
Study 39319904 — intervention group
Group type: EXPERIMENTAL
Intervention: Double antibiotic paste (DAP)
Number of subjects: 20
Study 39320250 — intervention group
Group type: EXPERIMENTAL
Intervention: da Vinci Xi system (DV-RARP)
Number of subjects: 100
Study 39320250 — intervention group
Group type: COMPARATOR
Intervention: Hugo RAS system (H-RARP)
Number of subjects: 100
Study 39320285 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution investigational SCS (HR-SCS)
Number of subjects: 18
Study 39320397 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon behaviors (e.g., establishing rapport, providing reassuring information)
Number of subjects: 30
Study 39320397 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid arm of Alliance A231701CD
Number of subjects: 30
Study 39320582 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 1142
Study 39320582 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 1142
Study 39320582 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 2 mg BID
Number of subjects: 1142
Study 39320582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1142
Study 39320582 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (all doses)
Number of subjects: 1142
Study 39320582 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 1142
Study 39320583 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg Q4W
Number of subjects: 1002
Study 39320583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1002
Study 39320594 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep education not supported by social media reminders
Number of subjects: 55
Study 39320594 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep education supported by social media reminders
Number of subjects: 55
Study 39320594 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 55
Study 39320879 — intervention group
Group type: EXPERIMENTAL
Intervention: Fever prevention using an automated surface temperature management device targeting 37.0 °C for 14 days or until ICU discharge.
Number of subjects: 677
Study 39320879 — intervention group
Group type: COMPARATOR
Intervention: Standard care with standardized tiered fever treatment on occurrence of temperature of 38 °C or greater.
Number of subjects: 677
Study 39320879 — intervention group
Group type: EXPERIMENTAL
Intervention: Fever prevention group
Number of subjects: 677
Study 39320879 — intervention group
Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 677
Study 39320882 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion axillary lymph node dissection (CALND)
Number of subjects: 1010
Study 39320882 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model for high nodal burden
Number of subjects: 1010
Study 39320882 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model for lobular breast cancer subgroup
Number of subjects: 1010
Study 39320906 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib, dosage and duration not specified
Number of subjects: 0
Study 39320907 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisugabalin 40 mg/d
Number of subjects: 366
Study 39320907 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisugabalin 80 mg/d
Number of subjects: 366
Study 39320907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 366
Study 39321205 — intervention group
Group type: EXPERIMENTAL
Intervention: Wild-type FA1090 strain
Number of subjects: 0
Study 39321205 — intervention group
Group type: EXPERIMENTAL
Intervention: Isogenic mutant FA1090 strain (lacking functional MtrCDE pump)
Number of subjects: 0
Study 39321205 — intervention group
Group type: COMPARATOR
Intervention: FA19 strain (mutant lacking functional MtrCDE pump)
Number of subjects: 0
Study 39321205 — intervention group
Group type: EXPERIMENTAL
Intervention: FA1090 strains in female mice
Number of subjects: 0
Study 39321347 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose dexamethasone (FD-DEX) 40 to 60 mg weekly
Number of subjects: 541
Study 39321347 — intervention group
Group type: COMPARATOR
Intervention: Lowered-dose dexamethasone (LD-DEX)
Number of subjects: 541
Study 39321362 — intervention group
Group type: EXPERIMENTAL
Intervention: Fidanacogene elaparvovec
Number of subjects: 45
Study 39321363 — intervention group
Group type: EXPERIMENTAL
Intervention: Tulisokibart (1000 mg on day 1 and 500 mg at weeks 2, 6, and 10)
Number of subjects: 135
Study 39321363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 39321363 — intervention group
Group type: EXPERIMENTAL
Intervention: Tulisokibart (for patients with a positive test for likelihood of response)
Number of subjects: 135
Study 39321363 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for patients with a positive test for likelihood of response)
Number of subjects: 135
Study 39321361 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziresovir (10 to 40 mg, according to body weight), administered twice daily for 5 days
Number of subjects: 244
Study 39321361 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered twice daily for 5 days
Number of subjects: 244
Study 39321361 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziresovir
Number of subjects: 244
Study 39321361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study 39321425 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient or low-titer aPLs
Number of subjects: 524
Study 39321425 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiphospholipid syndrome (APS)
Number of subjects: 524
Study 39321453 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based weekly survey for out-of-pocket costs
Number of subjects: 13
Study 39321757 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Stepped Alcohol Treatment with Contingency Management (ISAT + CM)
Number of subjects: 120
Study 39321757 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 120
Study 39322114 — intervention group
Group type: EXPERIMENTAL
Intervention: Medically supportive food and behavioral lifestyle program
Number of subjects: 355
Study 39322114 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 355
Study 39322173 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of cardiovascular risk factors and high burden of subclinical atherosclerosis
Number of subjects: 1000
Study 39322173 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrovascular pathology and intracranial atherosclerosis
Number of subjects: 1000
Study 39322237 — intervention group
Group type: EXPERIMENTAL
Intervention: PROVIDE model (n=187) - integrated mental health video consultation approach with five real-time video sessions
Number of subjects: 376
Study 39322237 — intervention group
Group type: EXPERIMENTAL
Intervention: PROVIDE model (n=187) - integrated mental health video consultation approach
Number of subjects: 376
Study 39322237 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=189) - provided by GPs through brief counselling and psychotropic medication prescriptions
Number of subjects: 376
Study 39322365 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter tricuspid valve intervention (TTVI)
Number of subjects: 483
Study 39322513 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaque rupture
Number of subjects: 232
Study 39322524 — intervention group
Group type: EXPERIMENTAL
Intervention: Olpasiran in addition to standard-of-care
Number of subjects: 2
Study 39322524 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelacarsen in addition to standard-of-care
Number of subjects: 2
Study 39322524 — intervention group
Group type: EXPERIMENTAL
Intervention: Olpasiran and pelacarsen
Number of subjects: 2
Study 39322526 — intervention group
Group type: EXPERIMENTAL
Intervention: High remnant cholesterol (> 20.5 mg/dL; n = 1,116)
Number of subjects: 3348
Study 39322526 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate remnant cholesterol (14‒20.5 mg/dL; n = 1,031)
Number of subjects: 3348
Study 39322526 — intervention group
Group type: EXPERIMENTAL
Intervention: Low remnant cholesterol (≤14.0 mg/dL; n = 1,201)
Number of subjects: 3348
Study 39322526 — intervention group
Group type: EXPERIMENTAL
Intervention: On-treatment remnant-C cut-off of 17 mg/dL (median)
Number of subjects: 3348
Study 39322526 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieving LDL-C <55 or 70 mg/dL
Number of subjects: 3348
Study 39322590 — intervention group
Group type: EXPERIMENTAL
Intervention: Delphi consensus exercise
Number of subjects: 15
Study 39322600 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident pregnancy over 1 year
Number of subjects: 2015
Study 39322600 — intervention group
Group type: COMPARATOR
Intervention: Comparison participants (non-pregnant)
Number of subjects: 2015
Study 39322611 — intervention group
Group type: EXPERIMENTAL
Intervention: dostarlimab+carboplatin-paclitaxel
Number of subjects: 118
Study 39322711 — intervention group
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Number of subjects: 0
Study 39322802 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P17 (100 mg/mL), citrate-free adalimumab biosimilar
Number of subjects: 232
Study 39322802 — intervention group
Group type: COMPARATOR
Intervention: R-ADA (100 mg/mL)
Number of subjects: 232
Study 39322802 — intervention group
Group type: COMPARATOR
Intervention: ADA-BioS (50 mg/mL)
Number of subjects: 232
Study 39322802 — intervention group
Group type: COMPARATOR
Intervention: Previous treatment with ADA-BioS
Number of subjects: 232
Study 39322802 — intervention group
Group type: COMPARATOR
Intervention: Previous treatment with pain at injection site
Number of subjects: 232
Study 39322802 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P17 treatment
Number of subjects: 232
Study 39322817 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy on the 1st, 7th, and 30th postoperative days; surgical wound care by nurses on the 7th, 14th, and 21st postoperative days.
Number of subjects: 249
Study 39322817 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight or obese status
Number of subjects: 249
Study 39322817 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary lymphadenectomy
Number of subjects: 249
Study 39322961 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab (70 mg or 140 mg) for migraine prophylaxis over 128 weeks.
Number of subjects: 701
Study 39322961 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab treatment after drug holiday.
Number of subjects: 701
Study 39322961 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug holiday (voluntary treatment interruption of up to 24 weeks).
Number of subjects: 701
Study 39323188 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 407
Study 39323258 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative thoracic epidural analgesia
Number of subjects: 66
Study 39323258 — intervention group
Group type: COMPARATOR
Intervention: Oral morphine
Number of subjects: 66
Study 39323258 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative pain management (both groups)
Number of subjects: 66